1 published in Bone Marrow Transplantation. The authors reported that HSV-1 shedding in oral fluid after hematopoietic SCT (HSCT) is a significant predictor for oral mucosal ulcerations in adult patients, thus being a promising marker of the epithelial lesion. However, the conditioning regimen proved to be a non-significant predictor of ulcerative mucositis (UM) in this study. Therefore, we would like to discuss some interrelations between intensity of conditioning therapy, viremia rates and UM frequency in our pediatric setting. Some of these cases were reported elsewhere. 2 Our study involved 120 patients of 1-21 years old (a mean of 12.4±5.9), comprising 56% males and 44% females, treated at R. Gorbacheva Memorial Institute of Children Hematology and Transplantology from 2002 to 2010. The patients with oncohematological disorders (mostly, acute leukemias, 73% of the total) underwent allo-HSCT from HLA-matched related or unrelated donors (38% and 62% of total group, respectively). The patients received peripheral blood stem cells or BM (60% and 40% of the total, respectively). Sixty-one recipients (51%) underwent myeloablative conditioning treatment (basically, BuCy protocols), while other patients were subjected to reduced-intensity conditioning (RIC), mostly, fludarabine-based treatment. GVHD prophylaxis was performed with CYA and MTX, at a standard schedule. In nonrelated HSCTs, antilymphocyte globulin treatment was added in 91 cases (76%), at 20 mg/m 2 daily. Acyclovir prophylaxis since day 0 was performed in 31 patients (26% of total).
To assess the degree of mucosal lesions, we used a WHO Oral Mucositis scale. Grade 1 corresponded to soreness and visible erythema, whereas grades 2-4 designated less or more severe mucosal ulcerations that caused feeding disability. Clinical mucositis grading was performed from day À 5 to day þ 60 post-HSCT. Peak scores were determined and taken for statistical evaluation. 3 Within this time period, 18 patients (15%) did not exhibit any oral mucosal ulcers (grade 0-1), whereas ulceration (UM grades 2-4) were registered in 44 (37%), 35 (29%) and 23 cases (19%), respectively. The entire study protocol was approved by the Institutional Review Board on Medical Ethics at the St. Petersburg State I. Pavlov Medical University. All patients gave their written informed consent, according to the Declaration of Helsinki.
DNA diagnostics of CMV, HSV and EBV was performed in peripheral blood leukocytes on a weekly basis, using commercial gene-specific PCR kits (Interlabservice, Moscow, Russia), at a cutoff value of 1000 copies/ml, as verified by quantitative PCR kits made by the same manufacturer, using appropriate plasmid controls. Statistical data were evaluated by common parametric and nonparametric criteria, using Statistica 6.0 software.
Persistence of HSV, EBV and CMV within 60 days after HSCT, determined as two or more sequential PCR-positive samples, was observed in 22-24% of the cases. Viral reactivation rates and mucosal ulceration did not depend on patients' gender, initial hematological diagnosis, stem cell source or graft origin (familial vs unrelated donor).
When assessing clinical significance of the post-transplant viremia, we revealed a clear dependence between HSV viremia and oral mucositis grade, in accordance with results reported by van der Beek et al. 1 Indeed, we have found a significant increase in oral ulceration rates among HSV-positive vs HSV-free cases (100% vs 75%, respectively; Po0.02).
Taking together the findings by van der Beek et al. 1 on salivary HSV excretion, and our data on HSV viremia, we may consider both HSV shedding in saliva and its persistence in blood cells as significant risk factors of UM post HSCT. Moreover, daily monitoring of mucosal ulceration (day À 3 through day þ 35 post-HSCT) has revealed longer terms of mucosal healing in patients with HSV viremia, as compared with HSV-free cases (19 ± 2 vs 14 ± 1 days; P ¼ 0.02).
Moreover, we have found that UM (grades 2-4) was more common after myeloablative treatment, than after RIC (92% vs 70%; P ¼ 0.03). In addition, a history of UM during previous cytostatic therapy proved to be associated with higher UM incidence after current conditioning treatment (94% vs 62.5%; P ¼ 0.002). Hence, a burden of the past and present tissue damage could be regarded as a predictor of mucosal ulceration after HSCT.
Following myeloablative conditioning, a significant dependence was shown between the grade of mucosal ulceration and HSV viremia rates, as seen in Figure 1 . Such dependence was not detectable in patients after reduced-intensity treatment (n ¼ 61; P ¼ 0.03).
Increased mucositis rates and severity associated with more intensive conditioning represent a dose-dependent relationship observed with various anticancer agents, both in conditioning regimens with or without TBI. [4] [5] [6] Common risk factors for severe mucositis include the amount of present chemotherapy, as well as previous exposure to cytostatic agents. 7, 8 For example, our in vitro study of irradiated cells illustrated a general concept that irreparable cell damage is strictly dose-dependent, both in sensitive blood cell populations and resistant resident cells. In our study, the mean duration of granulocytopenia was 30.1 days in cases of mild-degree mucositis (grades I-II), as compared with 38.2 days in UM (Po0.001), thus suggesting a certain dose dependence for cell damage/repair in mucosal epithelium and hematopoietic cell populations. Hence, both epithelial damage and leukocytopenia post HSCT may be associated with diminished repair abilities of recovering cell populations.
In summary, the intensity of conditioning regimen seems to be an important factor of tissue damage, whereas HSV positivity of saliva or blood leukocytes proved to be a good predictor for severe mucosal damage after intensive conditioning treatment.
